原料辞典検索/stearic-acid/STEARIC ACID
Tier 1 Monograph · SSOT 15 FieldsRaw .md (GEO) ↗
合成 (Synthetic)

STEARIC ACID

日本化粧品工業連合会 (JCIA) 表示名称: ステアリン酸
洗浄剤香料乳化剤乳化安定剤過脂肪剤
結論先行 エグゼクティブ規制・安全性ファクトボックスAEO / GEO CITATION ANCHOR

化粧品における ステアリン酸 (STEARIC ACID) のグローバル配合基準と処方特性とは?

ステアリン酸(標準 INCI: STEARIC ACID、CAS番号: 57-11-4)は、化粧品処方において主に洗浄剤, 香料, 乳化剤として配合される原料です。日本厚労省/JCIA(規制なし)、韓国MFDS(規制なし)、欧州CosIng(規制なし)など6大法域の法定基準下で管理され、通常 0.5–16.5%(適正安定域 pH 4–8)で処方されます。

7大トラック 国別・用途別 公式全成分表示名称マトリクス

各国公的告示原典のみ収録 · 機械翻訳・任意音訳ゼロ
7-Track Official Statutory Label Names for STEARIC ACID
法域・規制トラック公式全成分表示名称ワンクリックコピー
① 韓国 (MFDS 化粧品標準名称)STEARIC ACID (KR MFDS Registered)
② 韓国旧名称履歴 (301 リダイレクト)——
③ 欧州連合 (EU CosIng EC 1223/2009)STEARIC ACID
④ 米国一般化粧品 (US PCPC / MoCRA INCI)STEARIC ACID
⑤ 米国 FDA OTC モノグラフ有効成分名— (米国 OTC 対象外 / 一般化粧品原料)—
⑥ 中国 (NMPA IECIC 標準中国語名称)硬脂酸
⑦ 日本化粧品表示名称 / 医薬部外品外原規名称 (JCIA / MHLW)ステアリン酸 · [QD: ステアリン酸]

Layer 1 — 6大法域 法定配合上限および規制ステータス

Layer 1 Statutory Regulatory Limits Across 6 Regions for STEARIC ACID
法域規制ステータス配合上限制限条件および一次法源出典
韓国 (MFDS)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
欧州 (EU)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
米国 (FDA)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
中国 (NMPA)配合可能GMPIECIC Entry #8028
日本 (MHLW)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)
ASEAN (ACD)規制なしGMP公的化粧品原料目録収載 (GMP基準内使用)

Layer 2 — 毒性・安全性評価上限 (US CIR / EU SCCS / CN IECIC)

「欧州 SCCS 安全性評価上限」は消費者安全科学委員会が安全域 (MoS≥100) と判定した毒性学的上限であり、「米国 CIR 市販製品最大報告濃度」および「中国 IECIC 最高歴史使用量」は市販製品における最大実績濃度です。

Layer 2 Toxicological & Historical Safe Use Concentrations for STEARIC ACID
安全性評価基準適用範囲・用途安全濃度範囲判定結果および文献参照
中国 IECIC 最高歴史使用量leave_on≤ 20%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 07918 (2025)
中国 IECIC 最高歴史使用量rinse_off≤ 15%安全判定 (MoS≥100)NMPA IECIC (2025) Entry 07918 (2025)
⚠️ 参考用案内 (免責事項): 本辞典の成分名・規制上限・処方ガイドは研究開発の参考用です。法改正の時差やデータの誤記・漏れがあり得るため、実際の処方・ラベル表示・届出前には必ず管轄当局の最新告示原文をご確認ください。本情報の利用により生じた問題について運営主体は法的責任を負いません。
Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Emulsion / Creamn=15
Min 0.5% · Q1 1.25% · Median 2% · Q3 10% · Max 16.5%
Sunscreen / Colorn=12
Min 0.6% · Q1 1.875% · Median 2.95% · Q3 4.2% · Max 11%
Emulsion / Cream — Emulsion cream & lotion structural / conditioning agent
Verified Source: Global Starter Formulation Library Statistical Distribution (n=15, EVONIK 9 · GRANT 3 · SEPPIC 3) (cir_safety) · EVONIK 9 · GRANT 3 · SEPPIC 3
Typical Median: 2%

Layer 3 — 剤形別通常配合濃度 (四分位数 n≥5) & 物理化学・相溶性ガイド

Layer 3 Formulation Concentration Quartiles by Product Category for STEARIC ACID
剤形グループMin – Q1 – Median – Q3 – Max (%)処方役割・作用機序Source ID
剤形群 B — 乳液・エマルジョン・クリーム0.5% · 1.25% · 2% · 10% · 16.5%Emulsion cream & lotion structural / conditioning agentGlobal Starter Formulation Library Statistical Distribution (n=15, EVONIK 9 · GRANT 3 · SEPPIC 3)
剤形群 D — 日焼け止め (UV)・メイクアップ・ファンデーション0.6% · 1.875% · 2.95% · 4.2% · 11%Sun care & color cosmetics dispersion / sensory modifierGlobal Starter Formulation Library Statistical Distribution (n=12, EVONIK 6 · GRANT 5 · SEPPIC 1)
Cutaneous Permeation Science (500 Dalton Rule)MW: Macro/Complex · LogP: N/A

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Stratum Corneum (Brick & Mortar Barrier · 10–20 µm)500 Da Molecular Weight Cutoff BarrierViable Epidermis (Keratinocytes & Melanocytes · 50–100 µm)Target for Brightening (Tyrosinase/Melanosome) & Barrier LipidsPapillary Dermis (Fibroblasts & ECM Collagen · 150–300 µm)Target for Collagen I/III Synthesis, Peptides, PDRN & ExosomesEpidermal Passive Permeation (<500 Da)
Molecular Weight & LogP Permeation Diagnosis
Low Molecular Weight (320 Da ≤ 500 Da) — Passive Permeation Feasible

Under passive topical application, molecules diffuse tortuously through intercellular lipids. Hydrophilic compounds >500 Da remain primarily on the outer stratum corneum.

Estimated Target Depth
40–90 µm
Optimal Delivery System
Polyol Enhancer / Serum
Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Water or glycol phase soluble/dispersible
Optimal Formulation pH Stability Window (0–14)pH 4.0 – 8.0
0245.5791114

Outside pH 4–8, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C
25°C45°C60°C75°C85°C100°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator
O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)
HLB 11.5
W/O (3–6)Lamellar (8–10.5)O/W Emulsion (11–15)Solubilizer (15–19)O/W Droplet
Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation
Intercellular Lipid & Hydration Matrix
→
TEWL Reduction & Barrier Conditioning
2. Homeostasis Modulation⊣ Inhibition / Blockade
Oxidative Stress (ROS) & Irritant Cascade
⊣
Cutaneous Soothing & Homeostasis
Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

+ GLYCERIN+ CAPRYLIC/CAPRIC TR…+ TOCOPHEROL✕ Verify phase compati…STEARIC ACID
Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

代表商品名参考 (商標法第90条第1項第2号 記述的表示)
STEARIC ACID

商品名は研究者がグレードを識別するための参考表記であり、各商標権は原メーカーに帰属します。

学術・毒性・処方統合モノグラフ

Tier 1 Synthesis

本原料に紐づく NIH PubMed 査読付き論文アブストラクトおよび公的毒性評価報告書のみに基づいて作成された学術要約です。

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: STEARIC ACID | CAS No.: 57-11-4 | EC No.: 200-313-4 - Origin: SYNTHETIC | Functions: , , , , - Physicochemical Profile: Formula | MW /(Polymer/Complex) | / | Ionic Nature: non-ionic | CosIng/MFDS - Official Regional Label Names: US [STEARIC ACID] · EU [STEARIC ACID] · CN [硬脂酸] · JP [ステアリン酸] · JP Quasi-Drug [ステアリン酸] ■ [2. Dermatological Mechanism of Action & Functional Role] - STEARIC ACID functions primarily as , , , , in dermatological and cosmetic formulations. Classified under origin 'synthetic', it acts within the cosmetic vehicle or stratum corneum to deliver , , , , performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 8028 (硬脂酸)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 20.0% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 15.0% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [emulsion_cream] Typical range: 0.5 ~ 16.5% (Median 2.0%, Ref: Global Starter Formulation Library Statistical Distribution (n=15, EVONIK 9 · GRANT 3 · SEPPIC 3)) — Emulsion cream & lotion structural / conditioning agent - [sun_color] Typical range: 0.6 ~ 11.0% (Median 2.95%, Ref: Global Starter Formulation Library Statistical Distribution (n=12, EVONIK 6 · GRANT 5 · SEPPIC 1)) — Sun care & color cosmetics dispersion / sensory modifier ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Water Phase or Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.0 ~ 8.0 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Verify phase compatibility under extreme pH or high electrolyte loads - Synergy Pairings: GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL | Reference Trade Names: STEARIC ACID ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 42142203 (2026, Discov Nano): Development and preclinical evaluation of quiniodochlor-loaded nanostructured lipid carrier-chitosan gel for topical ant - PMID 41844721 (2026, Sci Rep): Bioactive-fat engineered nanostructured lipid carriers from Illipe butter: optimized design and enhanced in vitro anti-i - PMID 41556321 (2026, Pharm Dev Technol): Clobetasol propionate loaded nanostructured lipid carrier gel: formulation strategy and in vitro performance evaluation

関連査読付き学術論文 (NIH PubMed) (12)

Development and preclinical evaluation of quiniodochlor-loaded nanostructured lipid carrier-chitosan gel for topical antifungal therapy [PMID: 42142203 · 2026]
Biswas UK, Bose A, Naskar S, Jana M · Discov Nano (2026)

The rising incidence of superficial fungal infections and the limitations of conventional topical therapies necessitate the development of advanced, targeted delivery systems. This study aimed to develop and evaluate a novel quiniodochlor (QD)-loaded nanostructured lipid carrier (NLC) gel for enhanced topical antifungal therapy. QD-loaded NLCs were prepared by hot homogenization using stearic acid (solid lipid) and cinnamon oil (liquid lipid), stabilized with Tween &#xae; 80, and incorporated into a chitosan hydrogel. Formulations were characterized for particle size, polydispersity index (PDI), zeta potential, entrapment efficiency (EE%), drug release, and physicochemical stability. The developed gel was further evaluated for spreadability, extrudability, ex vivo skin permeation/retention, in vitro antifungal activity against Candida albicans, and in vivo skin irritation. The optimized NLCs exhibited nanoscale particle sizes (141.86-250.79) high EE% (&gt;&#x2009;98%), and low PDI (0.28-0.43). Despite a near-neutral zeta potential, colloidal stability was maintained, attributed to steric stabilization. The NLC gel showed a sustained drug release profile, significantly higher skin retention, and about 1.6-fold larger zone of inhibition against C. albicans compared to a marketed QD cream. Ex vivo studies confirmed enhanced dermal accumulation with negligible transdermal permeation. The formulation demonstrated excellent spreadability and extrudability, and elicited no signs of erythema or edema in an in vivo skin irritation model. The developed QD-NLC-chitosan gel presents a promising, safe, and effective topical strategy with enhanced skin targeting, sustained local release, and superior antifungal activity, demonstrating strong potential as an advanced therapeutic alternative for superficial mycoses.

Bioactive-fat engineered nanostructured lipid carriers from Illipe butter: optimized design and enhanced in vitro anti-inflammatory performance [PMID: 41844721 · 2026]
Kurniawansyah IS, Chaerunisaa AY, Akmalia NNN · Sci Rep (2026)

Despite the extensive use of synthetic and semi-synthetic lipids in nanostructured lipid carrier (NLC) systems, the utilization of Shorea spp. (Illipe butter or tengkawang fat), an indigenous natural solid lipid from Indonesia, remains unexplored. This study aimed to develop and optimize a Nanostructured Lipid Carrier (NLC) formulation using Illipe butter (Shorea spp.) as a natural solid lipid source. The NLC system was designed through a Box-Behnken design to evaluate the influence of solid lipid (Illipe butter and glyceryl monostearate), liquid lipid (oleic acid), and surfactant mixture (Tween 80 and glycerin) on physicochemical characteristics. The optimized formulation Nanostructured Lipid Carrier-Illipe Butter (NLC-IB) was incorporated into a gel base to produce an NLC gel formulation suitable for topical anti-inflammatory application. Characterization of the optimized NLC revealed a particle size of 276.9&#xa0;nm, PDI of 0.393, and zeta potential of&#x2009;-&#x2009;53.5&#xa0;mV, indicating good stability. Transmission electron microscopy showed spherical particles with an imperfect crystal (Type I) matrix. GC-MS analysis confirmed the retention of major fatty acids, particularly stearic acid (31.9%) and palmitic acid (18.2%), in the NLC system. In vitro anti-inflammatory evaluation using the BSA denaturation assay demonstrated moderate activity, with IC&#x2085;&#x2080; values of 197.23&#xa0;ppm (Illipe butter), 146.46&#xa0;ppm (NLC-IB), and 238.49&#xa0;ppm (E-NLC-IB). To our knowledge, this study represents one of the first systematic investigations of Illipe butter (Shorea spp.) as a solid lipid matrix in nanostructured lipid carrier systems.

Clobetasol propionate loaded nanostructured lipid carrier gel: formulation strategy and in vitro performance evaluation [PMID: 41556321 · 2026]
Diril M, Karata&#x15f; E, Karasulu HY · Pharm Dev Technol (2026)

Clobetasol propionate (CP) is a potent Class I corticosteroid widely used to treat dermatological conditions; however, its poor aqueous solubility limits bioavailability. In this study, a nanostructured lipid carrier (NLC)-based gel was developed via the microemulsion method to improve the topical delivery of CP. The formulation was optimized using stearic acid (solid lipid), Captex 300 (liquid lipid), Tween 20 and Span 80 (surfactants), and propylene glycol (co-surfactant), based on solubility and thermodynamic stability assessments. Vitamin E acetate was incorporated as an antioxidant to inhibit lipid oxidation and enhance formulation stability. The optimized CP-NLC (F5) formulation had a particle size of 75.96&#x202f;&#xb1;&#x202f;4.87&#x202f;nm, a zeta potential of -23.88&#x202f;&#xb1;&#x202f;4.10&#x202f;mV, and a polydispersity index (PDI) of 0.27&#x202f;&#xb1;&#x202f;0.11. Encapsulation efficiency was 93.72&#x202f;&#xb1;&#x202f;0.26%, and drug loading reached 100.69&#x202f;&#xb1;&#x202f;0.62%. Transmission electron microscopy (TEM) confirmed spherical morphology. The gel (CP-NLC-F5-G) prepared with Carbopol 934 demonstrated a pH of 5.58&#x202f;&#xb1;&#x202f;0.68 and drug content uniformity of 99.03&#x202f;&#xb1;&#x202f;1.18%. In vitro release studies using Franz diffusion cells revealed sustained CP release compared to a commercial product. Stability studies indicated long-term encapsulation retention, attributed to the antioxidant effect of Vitamin E acetate. These findings suggest the potential of CP-NLC systems for effective, sustained corticosteroid delivery with enhanced dermal retention.

Comparative in vivo assessment of hair-growth efficacy using nanostructured lipid carriers individually loaded with lavender oil or tea seed oil [PMID: 41552988 · 2026]
Sarhan OM, El-Noby EM, El-Shaat HA, Mostafa MSA, Gebril MI · Pharm Dev Technol (2026)

This study aimed to formulate nanostructured lipid carriers loaded with tea seed or lavender oil to enhance hair regrowth via improved follicular penetration, as an alternative to conventional alopecia therapies. NLCs were prepared by ultrasonication of stearic acid: essential oil mixtures into an aqueous phase containing either Tween 80 or Pluronic F127 as surfactants. Particle size, polydispersity index, zeta potential and TEM were measured. In vivo efficacy was evaluated in female Wistar albino rats given selected once-daily topical NLCs for 30&#x2009;days. DLS analysis showed that formulations F2 and F5 had mean particle sizes of 165&#x2009;&#xb1;&#x2009;3&#x2009;nm and 181&#x2009;&#xb1;&#x2009;6&#x2009;nm, respectively, whereas the mixed-oil formulation F3 aggregated into large droplets. Zeta potentials of -65&#x2009;&#xb1;&#x2009;2&#x2009;mV (F2) and -42&#x2009;&#xb1;&#x2009;3&#x2009;mV (F5) confirmed excellent electrostatic stability. TEM images verified roughly spherical, core-shell nanoparticles. In the in&#xa0;vivo study, F2 and F5 treatments increased mean hair lengths by 120% and 132% versus placebo ( p &#x2009;&lt;&#x2009;0.001), respectively, compared to a 116% increase with the commercial product. NLCs significantly enhanced follicular density, with the lavender oil formulation showing superior hair shaft integrity. These results demonstrate that Pluronic F127-stabilized NLCs carrying natural oils possess optimal physicochemical properties and promote hair regrowth.

Broad-Spectrum Antibacterial Activity of Postbiotic From Lacticaseibacillus paracasei BGP1 Against Multidrug-Resistant Skin Wound Pathogens [PMID: 41355606 · 2025]
Mohammadhosseinzadeh F, Arefian E, Khaleghi M, Keshmiri Neghab H, Kashef N · Microbiologyopen (2025)

The increasing problem of antibiotic resistance indicates the need for alternative therapeutic strategies for skin wound infections. While probiotics exhibit potential for developing such alternatives, the majority of antimicrobial studies focus on live cells or lysates and oral delivery. Notably, in dermatology, formulating products with live strains poses technical challenges due to stability issues in water-based systems. Postbiotics, substances made from probiotics, offer a promising, stable, and safe alternative. This study addresses the gap by evaluating the antibacterial potential of cell-free supernatants (CFSs) from six probiotic strains, with a specific focus on Lacticaseibacillus paracasei BGP1, against clinically relevant skin pathogens. CFSs were screened in vitro using agar well diffusion and broth microdilution assays against Staphylococcus aureus ATCC 25923, methicillin-resistant S. aureus (MRSA; UTMC 1442), Pseudomonas aeruginosa ATCC 27853, and P. aeruginosa PAO1. GC-MS analysis was used to identify bioactive compounds in the most promising CFS. Among the tested strains, BGP1 demonstrated both consistent inhibitory (MIC: 6.25&#x2009;mg/mL) and bactericidal (MBC: 12.5&#x2009;mg/mL) effects. GC-MS analysis identified palmitic acid (33.24%) and stearic acid (46.45%) as dominant bioactive compounds. These findings provide novel evidence that postbiotic metabolites from L. paracasei BGP1 represent a promising, broad-spectrum, stable, and nonliving candidate to conventional therapies for antibiotic-resistant skin wound infections. Further in vivo research is needed to evaluate their therapeutic potential and formulation in clinical settings.

Guerbet Alcohols, Ideal Substrates for the Sustainable Production of Branched Esters [PMID: 41303974 · 2025]
Montiel MC, M&#xe1;ximo F, G&#xf3;mez M, Murcia MD, Ortega-Requena S, Bastida J · Materials (Basel) (2025)

Saturated and branched high molecular weight organic esters are highly valued as emollients in the cosmetic industry due to their superior properties. Their saturated character provides resistance to oxidation and rancidity. Additionally, their branched structure endows them with low melting temperatures, enabling them to remain liquid over a broad temperature range. These esters can be obtained from branched alcohols, branched fatty acids or both, using chemical or enzymatic processes. Among branched alcohols, Guerbet alcohols stand out. Due to their characteristic properties as branched, saturated alcohols with superior oxidative stability and extremely low volatility, they are proposed as excellent substrates for the enzymatic synthesis of these compounds. This study represents the first investigation into the biocatalytic synthesis of three specific esters: those formed between 2-octyl-1-dodecanol (C20 Guerbet alcohol) and the fatty acids myristic (MA), palmitic (PA), and stearic acid (SA). To achieve this, an environmentally sustainable biocatalytic process was developed. The synthesis involves a solvent-free esterification catalyzed by the commercial immobilized lipase, Lipozyme &#xae; 435, conducted within a vertically stirred, thermostated batch tank reactor. Optimal conditions for lipase concentration and temperature were established, and the sustainability of the process was successfully quantified using various "green metrics".

Development and optimization of Moxifloxacin solid lipid nanoparticles via double emulsion organic solvent free technique applying Box-Behnken experimental design [PMID: 41291000 · 2025]
Elshazly EM, Arafa MG, Nour SA · Sci Rep (2025)

The current research proposes the preparation of Moxifloxacin-loaded solid lipid nanoparticles through a solvent-free double emulsion technique, to overcome chronic wound healing limitation. The independent variables: stearic acid, Span 80, and Tween 80 were optimized via Box-Behnken design, based on entrapment efficiency (EE%), zeta potential (ZP), and particle size (PS). To statistically optimize the formulation variables, a three-factor, three-level (3&#xb3;) design involving 15 runs was employed and optimization was carried out to attain maximum EE% and ZP and minimum PS yielding an overall desirability of 0.851. Results indicated that increasing stearic acid enhanced EE%, Span 80 increase PS, and Tween 80 improved ZP. The Optimized SLNs formula had a ZP of -&#x2009;52.4 mV, EE% of ~&#x2009;79.6% and PS of 257&#xa0;nm. Chemical compatibility was emphasized using FTIR, and XRD studies revealed reduced drug crystallinity within the lipid matrix, which confirmed successful encapsulation. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) imaging revealed nanoparticles with defined spherical shape and smooth surface. The optimized formula is anticipated to enhance dermal distribution and prolonged antibiotic release, thereby offering an efficient therapeutic strategy for the management of chronic wounds.

Development and Evaluation of Nystatin-Loaded Novasomal Gel for the Treatment of Candida albicans Infection: In Vitro Microbiological and Skin Compatibility Study [PMID: 41149379 · 2025]
Mustafa MA, Fahad M, Mughal M, Rasheed N, Alqahtani SS, Iqbal MZ · Gels (2025)

Candida infections pose a significant health threat, and conventional antifungal drugs like nystatin are limited due to poor solubility, skin permeability, and frequent dosage requirements. Nystatin effectively targets Candida species by disrupting cell membranes, but formulation issues hinder clinical use. Lipid-based vesicular carriers, or novasomes, provide controlled, prolonged drug release and enhanced skin penetration. This study focuses on developing nystatin-loaded novasomal gels as an advanced drug delivery system to enhance therapeutic efficacy, bioavailability, and patient compliance. The formulation was prepared using a modified ethanol injection technique, combining stearic acid, oleic acid, Span 60, cholesterol, and Carbopol to produce a stable transdermal gel. Comprehensive in vitro characterization using FTIR, SEM, XRD, and thermal analysis confirmed the chemical compatibility, morphological uniformity, and physical stability of the nystatin-loaded novasomal gel. Entrapment efficiency differed significantly among the formulations ( p &lt; 0.05), with F7 achieving the highest value (80%). All formulations maintained pH levels within the skin-friendly range of 5.5 to 7.0. Viscosity measurements, ranging from 3900 &#xb1; 110 to 4510 &#xb1; 105 cP, confirmed their appropriate consistency for dermal use. Rheological analysis showed a dominant elastic response, as indicated by storage modulus values consistently higher than the loss modulus. Particle size ranged from 4143 to 9570 nm, while PDI values remained below 0.3, reflecting uniform particle distribution. Zeta potential values were strongly negative, supporting physical stability. XRD studies indicated reduced crystallinity of nystatin within the formulations, while FTIR confirmed drug-excipient compatibility. SEM images showed spherical particles within the micrometer range. In vitro release studies demonstrated sustained drug release over 12 h, with F6 releasing the highest amount. The novasomal gel formulations-maintained stability for 30 days, with no notable alterations in pH, viscosity, or entrapment efficiency. Antifungal evaluation showed a larger inhibition zone (23 &#xb1; 2 mm) compared with the plain drug solution (15 &#xb1; 1.6 mm), while the MIC value was reduced (4.57 &#xb5;g/mL), indicating greater potency. Skin irritation assessment in rats revealed only minor, temporary erythema, and the calculated Primary Irritation Index (0.22) confirmed a non-irritant profile. These findings suggest that the developed novasomal gel offers a promising approach for enhancing the treatment of fungal infections by enabling prolonged drug release, minimizing dosing frequency, and improving patient compliance.

Structural color generation in lipid-based cosmetics: Lamellar nanosheets from skin-identical fatty acids [PMID: 41033243 · 2026]
Eom JS, Park G, Liu X, Lee DS, Shin J, Choi YN, Jang J, Lee JB, Bae JK, Oh H, Hong SK · Colloids Surf B Biointerfaces (2026)

There is growing interest in pigment-free, biocompatible systems that generate structural color for cosmetic applications. This study presents pearlescent cosmetic formulations composed of skin-identical long-chain fatty acids, stearic acid (C18) and behenic acid (C22), that self-organize into multilamellar nanosheet structures in aqueous media. These formulations exhibited vivid, composition-dependent structural colors in the visible region, consistent with constructive interference of reflected light within nanosheet-based lamellar domains. Wavelength shifts were observed in the reflectance spectra as the ratio of stearic to behenic acid varied, indicating tunable optical properties. SAXS confirmed multilamellar structures with interlamellar spacing that varied systematically with composition. This study is the first to demonstrate structural color generation from physiologically relevant fatty acids naturally present in the human stratum corneum. These findings offer a skin-compatible, pigment-free design strategy for multifunctional cosmetic formulations that combine visual aesthetics with biological relevance.

Dual-drug nanostructured lipid carriers of spironolactone and 2-deoxy-D-ribose for targeted follicular delivery in androgenetic alopecia [PMID: 42218358 · 2026]
Kayal P, Mishra MK, Jawahar N · Drug Deliv Transl Res (2026)

Androgenetic alopecia (AGA) is a multifactorial condition driven by dihydrotestosterone (DHT)-induced follicular miniaturization and reduced perifollicular angiogenesis. Existing treatments such as finasteride, minoxidil, and dutasteride often show limited efficacy and systemic side effects like sexual dysfunction or cardiovascular issues, necessitating targeted approaches. The present study developed dual-drug nanostructured lipid carriers (NLCs) co-delivering spironolactone (SL), an anti-androgen, and 2-deoxy-D-ribose (2dDR), a pro-angiogenic agent, for synergistic follicular regeneration. NLCs were prepared by the hot microemulsion method, incorporating stearic acid as a solid lipid and fenugreek oil as a liquid lipid, with Span 80/Tween 80 surfactants. A Central Composite Design (CCD) was optimised to achieve minimal particle size and optimal zeta potential by varying lipid ratios and surfactant levels. The formulations were characterized by particle size analysis and zeta potential measurements, differential scanning calorimetry (DSC), X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FTIR), scanning electron microscopy (SEM), and in vitro drug release kinetics. Cytotoxicity and dihydrotestosterone (DHT)-protection assays were performed using human dermal papilla cells (hDPCs). Optimized SL-2dDR NLCs exhibited a particle size of 343.03&#x2009;&#xb1;&#x2009;9.0&#xa0;nm, a PDI of 27.97&#x2009;&#xb1;&#x2009;2.84%, and a zeta potential of -20.13&#x2009;&#xb1;&#x2009;0.40&#xa0;mV. Entrapment efficiency reached 99.00&#x2009;&#xb1;&#x2009;0.5% for SL and 98.75&#x2009;&#xb1;&#x2009;0.7% for 2dDR. DSC and XRD confirmed amorphous drug dispersion, while SEM revealed irregular, porous morphology favorable for follicular adhesion. In vitro release followed Higuchi kinetics for SL (R 2 &#x2009;=&#x2009;0.994) and Hixson-Crowell for 2dDR (R 2 &#x2009;=&#x2009;0.985). MTT assays demonstrated concentration-dependent cytoprotection against DHT-induced cytotoxicity, maintaining 82% cell viability at 50&#xa0;&#xb5;g/mL. The dual-drug NLC system represents a promising targeted therapy for AGA, combining anti-androgenic and pro-angiogenic mechanisms while minimizing systemic exposure.

Emulsome-Based Nanocarrier System for Controlled 4-Phenylbutyric Acid Delivery and Mechanistic Mitigation of Arsenical-Induced Skin Injury via Foam Application [PMID: 41599160 · 2025]
Viswaroopan N, Ghosh M, Kshirsagar SM, Khan J, Toral-Orduno J, Srivastava RK, Athar M, Banga AK · Pharmaceutics (2025)

Background : Lewisite, a potent chemical warfare agent, induces rapid and progressive cutaneous damage, necessitating treatment strategies that offer both immediate decontamination and prolonged therapeutic action. This study aimed to develop and evaluate a composite topical formulation comprising 4-phenylbutyric acid (4-PBA)-loaded emulsomes embedded within a foam vehicle to address both aspects of vesicant-induced skin injury intervention. Methods : Emulsomes composed of a stearic acid-cholesterol solid lipid core stabilized by a lecithin shell were prepared via thin film hydration and optimized by varying lipid ratios and drug loading parameters. Formulations were characterized for drug loading, particle size, and zeta potential. Physicochemical compatibility was assessed using Fourier transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) analyses. Stability was evaluated under accelerated refrigerated (25 &#xb0;C/60% RH) and room temperature (40 &#xb0;C/75% RH) conditions. The optimized formulation was incorporated into a foam base and evaluated for decontamination efficiency, drug release kinetics, in vitro permeation, and in vivo efficacy. Results : The selected formulation (E2) exhibited high drug loading (17.01 &#xb1; 0.00%), monodisperse particle size (PDI = 0.3 &#xb1; 0.07), and stable zeta potential (-40 &#xb1; 1.24 mV). FTIR and DSC confirmed successful encapsulation with amorphous drug dispersion. The emulsome-foam demonstrated dual functionality: enhanced decontamination (66.84 &#xb1; 1.27%) and sustained release (~30% over 24 h), fitting a Korsmeyer-Peppas model. In vitro permeation showed significantly lower 4-PBA delivery from E2 versus free drug, confirming sustained release, while in vivo studies demonstrated therapeutic efficacy. Conclusions : This emulsome-foam system offers a promising platform for topical treatment of vesicant-induced skin injury by enabling both immediate detoxification and prolonged anti-inflammatory drug delivery.

Fatty Acids Pattern, Essential Oil Content and Constituents of Some Sage Species (Salvia sp.) Native to Iran: Usable in Food Industry [PMID: 41334231 · 2025]
Mohammadi YV, Khorshidi J, Nazari F · Food Sci Nutr (2025)

The genus Salvia is a rich source of bioactive compounds with diverse applications in traditional medicine, as well as in the food, and pharmaceutical industries. This study evaluated the essential oil content and composition, seed oil yield, and fatty acid profiles of five native Iranian Salvia species ( S. nemorosa , S. spinosa , S. syriaca , S. palaestina , and S. multicaulis ) cultivated under uniform ecological conditions. Essential oils were extracted using a Clevenger apparatus based on the hydrodistillation method, while seed oils were obtained via Soxhlet extraction with hexane as the solvent. Both were subsequently analyzed by GC-MS and GC-FID. Results revealed significant interspecific variation. Essential oil content ranged from 0.014% (v/w) in S. nemorosa to 0.37% (v/w) in S. multicaulis . In contrast, the highest seed oil content (53.3% v/w) was found in S. nemorosa , while the lowest (18% v/w) was recorded in S. syriaca . S. nemorosa was rich in spathulenol and caryophyllene derivatives, whereas S. spinosa was dominated by isopentyl isovalerate. S. syriaca and S. palaestina primarily contained germacrene D, while S. multicaulis showed high levels of isoborneol, bornyl acetate, and 1,8-cineole. Palmitic, stearic, linoleic, and linolenic acids were detected in the seed oil of all studied Salvia species. S. multicaulis exhibited the highest levels of palmitic (10.92%&#x2009;&#xb1;&#x2009;0.33% v/w) and linoleic acid (52.57%&#x2009;&#xb1;&#x2009;4.57% v/w), S. palaestina had the highest stearic acid content (2.92%&#x2009;&#xb1;&#x2009;0.045% v/w), and S. nemorosa contained the highest linolenic acid level (46.3%&#x2009;&#xb1;&#x2009;0.594% v/w). Overall, S. multicaulis stood out for its high essential oil content, rich in isoborneol and bornyl acetate, whereas S. nemorosa exhibited the highest seed oil content dominated by linolenic acid. These findings suggest that S. multicaulis and S. nemorosa are promising candidates for essential oil and edible oil production, respectively, offering valuable potential for application in the pharmaceutical, cosmetic, and food industries.

よくある質問 (FAQ)

Q1. ステアリン酸 (STEARIC ACID) の各国公式全成分表示名称(7トラック)はどのように異なりますか?
日本化粧品工業連合会(JCIA)表示名称は 'ステアリン酸'、米国PCPC・欧州CosIng INCIは 'STEARIC ACID'、中国NMPA IECIC標準中国語名は '硬脂酸' です。
Q2. ステアリン酸 (STEARIC ACID) のグローバル6大法域における法定配合基準 (Layer 1) は?
6大法域規制ステータス — 日本(JP): none、韓国(KR): none、欧州(EU): none、米国(US): none、中国(CN): allowed、ASEAN: none。
Q3. 処方設計における ステアリン酸 (STEARIC ACID) の通常配合濃度 (Layer 3) と適正 pH は?
主要剤形 (emulsion_cream) において通常 0.5〜16.5%(中央値 2%)で配合され、適正pH範囲は 4〜8 です。
Q4. ステアリン酸 (STEARIC ACID) の配合禁忌 (Incompatibilities) と推奨シナジー成分は?
推奨シナジーペアは GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, TOCOPHEROL、配合上の注意点は Verify phase compatibility under extreme pH or high electrolyte loads です。